In specific settings, DPP4 inhibitors enhance antitumor immunity by preserving the functional integrity of chemokines, such as CXCL10 (15), whereas DPP4 inhibition sustains the ability of CXCL10 to recruit CXCR3-expressing lymphocytes to the tumor parenchyma by preventing its enzymatic truncation, thereby improving immune cell trafficking and amplifying the efficacy of immunotherapies, including ICIs. This evidence concerns the gene CXCR3 and neoplasm.